Effect of treatment with phenobarbital and stiripentol on carbamazepine‐induced teratogenicity and reactive metabolite formation

Teratology

Volumn 52, Issue 6, 1995, Pages 324-332

  Finnell, Richard H ^a   Bennett, Gregory D ^a   Slattery, John T ^b   Amore, Benny M ^b   Bajpai, Manoj ^b   Levy, René H ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DRUG METABOLITE; PHENOBARBITAL; STIRIPENTOL;

ANIMAL EXPERIMENT; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG DOSE; FETOTOXICITY; FETUS; INTRAPERITONEAL DRUG ADMINISTRATION; MATERNAL SERUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; CYTOCHROME P-450 ENZYME SYSTEM; DIETHYLCARBAMAZINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FETUS; LIVER; MALE; MICE; MICE, INBRED STRAINS; PHENOBARBITAL; PLACENTA; PREGNANCY; PROTEIN BINDING;

EID: 0029552422     PISSN: 00403709     EISSN: 10969926     Source Type: Journal    
DOI: 10.1002/tera.1420520603     Document Type: Article

References (51)

1. A rapid method for detecting malformations in rat fetuses
2. Anticonvulsant drugs in monotherapy. Effects on the fetus
3. Conversion of phenytoin to reactive metabolites in rat liver microsomes
4. Modified benzyl alcohol clearing of alizarin stained specimens without loss of flexibility
5. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiological and experimental findings spanning three decades. II. Human studies
6. Comparative study on the teratogenicity of some antiepileptics in the rat
7. The teratogenic effects of carbamazepine in the CD‐1 mouse fetus
8. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD‐1 mouse fetus
9. Phenytoin‐induced teratogenesis: A mouse model
10. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiological and experimental findings spanning three decades. I. Animal studies
11. Failure of epoxide formation to influence carbamazepine‐induced teratogenesis in a mouse model
12. Clinical and experimental studies linking oxidative metabolism to phenytoin‐induced teratogenesis
13. Differences in the pattern of phenytoin induced malformations following stiripentol coadministration in three inbred mouse strains
14. Protection from phenytoin‐induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model
15. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils
16. Malformations and minor anomalies in the children of epileptic mothers: Preliminary results of a prospective Helsinki study
17. Fetal head growth retardation associated with maternal antiepileptic drugs
18. Pattern of malformations in the children of women treated with carbamazepine during pregnancy
19. Teratogenicity of antiepileptic drugs: Analysis of possible risk factors
20. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs
21. Carbamazepine epoxide
22. Carbamazepine dose requirements during stiripentol therapy: Influence of cytochrome P‐450 inhibition by stiripentol
23. Carbamazepine and carbamazepine‐10, 11‐epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: Pharmacokinetics and clinical effects
24. Human anti‐cytochrome P450 antibodies in aromatic anticonvulsant‐induced hypersensitivity reactions
25. Congenital rib anomalies in a fetus exposed to carbamazepine
26. Metabolism of carbamazepine Drug Metab
27. Pharmacogenetics and drug interactions: Role in antiepileptic drug‐induced teratogenesis
28. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbamazepine
29. Protein measurement with the folin phenol reagent
30. Outcome of pregnancy in women with epilepsy
31. In vitro inhibition of rat brain cytochrome P‐450‐mediated naphthalene hydroxylation
32. Ex vivo inhibition of rat brain cytochrome P‐450 activity by stiripentol
33. The teratological effects of anticonvulsants and the effects on pregnancy and birth
34. Carbamazepine: Absorption, distribution, and excretion
35. Multi‐institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: Report of a collaborative study group in Japan
36. Carbamazepine and spina bifida
37. Decreased abnormal pregnancy outcome in offspring of epileptic women in the last decade: Relationship to maternal antiepileptic therapy
38. The 10,11‐epoxide‐10, 11 ‐diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: Effect of dose, comedication, and relation to outcome of pregnancy
39. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein‐nature
40. Phenytoin and carbamazepine in production of cleft palates in mice: Comparison of teratogenic effects
41. An investigation of the formation of cytotoxic, protein‐reactive and stable metabolites from carbamazepine in vitro
42. The effect of enzyme induction on the cytochrome P450‐mediated bioactivation of carbamazepine by mouse liver microsomes
43. Cranial nerve agenesis in a fetus exposed to carbamazepine
44. The relation of mating, ovulation, and the estrus smear in the house mouse to the time of day
45. Teratogenicity of antiepileptic drugs
46. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice
47. Teratogenic effect of carbamazepine
48. Teratogenicity of carbamazepine in rats
49. The role of ultrasound in the early diagnosis of fetal structural defects following maternal anticonvulsant therapy